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Foxp3+ regulatory T (Treg) cells maintain immune
homeostasis by limiting different types of inflamma-
tory responses. Here, we report that miR-146a, one
of the miRNAs prevalently expressed in Treg cells,
is critical for their suppressor function. The defi-
ciency of miR-146a in Treg cells resulted in a break-
down of immunological tolerance manifested in
fatal IFNg-dependent immune-mediated lesions in a
variety of organs. This was likely due to augmented
expression and activation of signal transducer and
activator transcription 1 (Stat1), a direct target of
miR-146a. Likewise, heightened Stat1 activation
in Treg cells subjected to a selective ablation of
SOCS1, a key negative regulator of Stat1 phosphor-
ylation downstream of the IFNg receptor, was asso-
ciated with analogous Th1-mediated pathology.
Our results suggest that specific aspects of Treg
suppressor function are controlled by a single
miRNA and that an optimal range of Stat1 activa-
tion is important for Treg-mediated control of Th1
responses and associated autoimmunity.
INTRODUCTION
A variety of pathologies are caused by the immune responses to
‘‘self’’ and environmental nonmicrobial antigens, to microbial
antigens derived from commensal microorganisms, and to infec-
tious agents. Regulatory T (Treg) cells limit ‘‘collateral damage’’
resulting from protective immunity to infection and suppress
sterile inflammation as well as unwanted immune responses to
‘‘self’’ and allergens (Belkaid and Tarbell, 2009; Lu and Ruden-
sky, 2009; Sakaguchi, 2005). Suppressive function of Treg cells
is indispensable for the immune homeostasis and survival of
higher organisms; Treg cell ablation in healthy adult mice leads914 Cell 142, 914–929, September 17, 2010 ª2010 Elsevier Inc.to a fatal, aggressive lympho- and myeloproliferative autoim-
mune syndrome (Kim et al., 2007). X chromosome-encoded
transcription factor Foxp3 plays a pivotal role in differentiation,
homeostasis, and function of Treg cells. Foxp3 loss-of-function
mutations cause systemic immune-mediated lesions similar to
those observed upon chronic Treg cell ablation (Fontenot
et al., 2003; Hori et al., 2003; Khattri et al., 2003). Analyses of
T cells expressing GFP-tagged null and functional Foxp3 alleles
and genome-wide analysis of Foxp3 binding genes showed that
Foxp3 directly or indirectly controls several thousand genes in
Treg cells (Fontenot et al., 2005; Gavin et al., 2007; Lin et al.,
2007; Zheng et al., 2007; Lu et al., 2009; Marson et al., 2007).
These studies also revealed that a number of genes constitu-
tively up- or downregulated in Treg cells in a Foxp3-dependent
manner undergo corresponding changes, albeit transient and
less prominent, in activated effector T cells. This sizable cluster
of ‘‘Foxp3-amplified’’ genes includes those serving as hallmarks
of Treg cells (CTLA4, CD25, and GITR) and playing important
functional roles in their homeostasis and function (Gavin et al.,
2007; Lin et al., 2007; Zheng et al., 2007; Marson et al., 2007).
These results suggested that Foxp3 acts in an ‘‘opportunistic’’
manner by amplifying and stabilizing expression of genes bene-
ficial to Treg cell function.
In addition to coding genes, the ‘‘Foxp3-amplified’’ cluster
also includes several small noncoding RNA known as micro-
RNAs (miRNAs) (Cobb et al., 2006). Notably, miRNAs serve as
important regulators of Treg cell homeostasis and function in
both basal and inflammatory settings (Chong et al., 2008; Liston
et al., 2008; Zhou et al., 2008). Ablation of miRNA precursor-pro-
cessing enzyme Dicer in Treg cells results in a reduction in their
numbers and suppressive capacity in healthy mice harboring
both Dicer-deficient and -sufficient Treg cells and a complete
loss of suppressor function in diseased mice lacking wild-type
Treg cells (Liston et al., 2008). Consequently, the generalized
depletion of miRNAs in Treg cells leads to a fatal early-onset
autoimmune pathology indistinguishable from that in Foxp3
mutant mice devoid of Treg cells (Chong et al., 2008; Liston
et al., 2008; Zhou et al., 2008). These results and the description
of a subset of miRNAs differentially expressed in regulatory
versus effector T cells (Cobb et al., 2006) raised a question as
to how individual miRNAs present in increased amounts in
Treg cells contribute to distinct aspects of their homeostasis
and function. In this regard, miR-155, a well-known onco-miR
(cancer-associated micro-RNA), is constitutively expressed in
high amounts in Treg cells in a Foxp3-dependent manner,
whereas T cells lacking Foxp3, B cells, and myeloid cells tran-
siently upregulate miR-155 upon activation (Androulidaki et al.,
2009; O’Connell et al., 2007; Thai et al., 2007). Our previous
studies showed that miR-155 confers heightened responsive-
ness of Treg cells to their key survival and growth factor, IL-2,
thereby maintaining their numbers in a competitive environment.
However, miR-155 is largely dispensable for Treg suppressor
function (Lu et al., 2009).
Like miR-155, miR-146a is highly expressed in Treg cells and
is induced upon activation of effector T cells and myeloid cells.
In the latter, miR-146a acts as a negative feedback regulator to
limit TRAF6 and IRAK1/2-mediated signaling in inflammatory
settings (Hou et al., 2009; Taganov et al., 2006), whereas in acti-
vated human T cells, miR-146a has been suggested to oppose
apoptosis and IL-2 production (Curtale et al., 2010). Thus, we
explored a role for miR-146a in Treg cells and found that this
microRNA is essential for the ability of Treg cells to restrain
IFNg-mediated pathogenic Th1 responses and associated
inflammation. In Treg cells, miR-146a-mediated downregulation
of Stat1, a key transcription factor required for Th1 effector cell
differentiation, was necessary for Treg ability to suppress Th1
responses. Furthermore, relieving negative regulation of Stat1
activation in Treg cells using an alternative genetic approach
resulted in a breakdown of immune homeostasis similar to that
observed in mice harboring miR-146a-deficient Treg cells.
Thus, our results suggest that a specific miRNA overrepresented
in Treg cells ensures their suppressor function by maintaining an
optimal threshold of cytokine receptor-dependent activation of
transcription factors crucial for a particular type of immune
response.
RESULTS
Elevated miR-146a Expression in Treg Cells
To identify miRNAs essential for controlling Treg cell function,
we consideredmiRNAs differentially expressed between Foxp3+
Treg cells and Foxp3- non-Treg CD4+ T cells (Cobb et al.,
2006; data not shown). Among miRNA overrepresented in Treg
cells, miR-146 was particularly prominent. This miRNA has
been implicated in negative regulation of immune cell function,
specifically in negative feedback regulation of myeloid cell
activation (Taganov et al., 2006). To study the role of miR-146
in Treg cells, we first sought to confirm the high amounts
of miR-146 in Treg cells. Since mature miR-146a and miR-
146b sequences differ by two nucleotides, it was difficult to
distinguish whether miR-146a or miR-146b or both are present
in increased amounts in Treg cells. To address this issue, we
performed stem-loop based Taqman real-time RT-PCR assay,
which allowed us to distinguish miRNAs within the same
family (Chen et al., 2005). As shown in Figure S1A (available
online), the miR-146a expression in CD4+CD25+Treg cells wassharply augmented in comparison to that in CD4+CD25-
CD62Lhi-naive T cells, while miR-146b expression was much
lower. Analysis of Treg and non-Treg cell subsets isolated
frommiR-146a-deficient mice suggested that the small increase
in miR-146b signal in Treg cells was likely due to miR-146a
expression since miR-146b expression could no longer be
observed in miR-146a-deficient Treg cells (Figure S1A). In
support of this notion, examination of primary miRNA transcripts
demonstrated that pri-miR-146a but not pri-miR-146b was
elevated in Treg cells compared with naive T cells (Figure S1B).
Thus, miR-146a, but not miR-146b, was highly upregulated in
Treg cells.
miR-146a Deficiency Resulted in Increased Numbers
but Impaired Function of Treg Cells
To assess a role for miR-146a in Treg cells, we examined Foxp3+
Treg cell subsets in the thymus and in the peripheral lymphoid
organs of miR-146a-deficient mice. These mice develop severe
lympho- and myeloproliferative syndrome at 6 months of age
(M.P.B., K.D.T. and D.B., unpublished data). Therefore,
we analyzed miR-146a-deficient and littermate control mice at
6–8 weeks of age prior to development of any clinical signs of
autoimmune or inflammatory disease and found comparable
sizes of different thymocyte and peripheral lymphoid and mye-
loid cell subsets (Figures S1C–S1F; data not shown). Moreover,
T cell activation status was also similar to that observed in
the wild-type (WT) littermates (Figure S1I; data not shown).
In contrast to a reduction in Treg cell numbers observed in
mice lacking miR-155 (Lu et al., 2009), miR-146a-deficient
mice contained significantly increased numbers of Foxp3+
Treg cells in the periphery, but not in the thymus (Figures S1G
and S1H). Consistent with its increased size, the miR-146a-defi-
cient Treg cell subset exhibited heightened proliferative activity
reflected in augmented expression of Ki67 and a modest
increase in several activation markers (Figure S1J; data not
shown).
As miR-146a is an important negative regulator of myeloid cell
responses to cytokines and Toll-like receptor (TLR) ligands, it
was possible that increased miR-146a-deficient Treg cell
numbers were due to a heightened activation status of dendritic
cell (DC), but not a cell-intrinsic effect of miR-146a deficiency.
It was also possible that altered immune effector function in
Mirn146a/ mice masked potential defects in miR-146a-defi-
cient Treg cell-mediated suppression. To explore these possibil-
ities we performed a series of bonemarrow (BM) transfer studies
(Figure 1A). First, we transferred BM cells from miR-146a-defi-
cient or -sufficient littermates mixed with BM cells from
Ly5.1+B6mice at a 1:1 ratio into Rag2- or TCRbd-deficient recip-
ients. Analysis of the resulting chimeric animals (Mirn146a//
B6) allowed us to discriminate between cell-intrinsic and cell-
extrinsic effects of miR-146a deficiency on increased Treg cell
numbers. Second, by performing cotransfers of Ly5.1+Foxp3KO
BM cells in place of Ly5.1+B6 BM, we generated mice
(Mirn146a//Foxp3KO) in which all Treg cells lack miR-146a
because Foxp3KO precursors fail to generate Treg cells, but all
other BM-derived cells originate from both miR-146a-deficient
and -sufficient BM. These mice allowed us to examine the func-
tion of miR-146a-deficient Treg cells in a miR-146a-sufficientCell 142, 914–929, September 17, 2010 ª2010 Elsevier Inc. 915
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environment. Like chimeric mice reconstituted with Foxp3KO
BM alone, Mirn-146a//Foxp3KO chimeras developed severe
immune-mediated pathology including conjunctivitis, blephari-
tis, and dermatitis as early as 5 weeks after BM transfer and
became moribund soon thereafter (Figure 1B). Histological
examination ofMirn146a//Foxp3KO chimeras 6–7 weeks after
transfer showed massive lymphocyte activation and tissue
infiltration in the lung, liver, and skin similar to that observed in
mice harboring Dicer-deficient Treg cells (Chong et al., 2008;
Liston et al., 2008; Zhou et al., 2008). In contrast, there were
no clinical or histological signs of immune-mediated lesions in
control Mirn146a//B6 chimeras where both miR-146a-defi-
cient and -sufficient Treg cells were present (Figure S2).
The disease inMirn146a//Foxp3KO was not due to reduced
numbers of Treg cells. Mirn146a//Foxp3KO chimeras, which
developed autoimmune pathology, had increased numbers of
Treg cells compared with controlMirn146a+/+/Foxp3KO animals
(Figures 1C–1E). Importantly, the difference in miR-146-deficient
versus -sufficient Treg cell numbers was also observed in
Mirn146a//B6 chimeric mice where miR-146a-deficient Treg
cells compete with their wild-type counterparts (Figures 1F and
1G). The observed increase in the proportion of the miR-146a-
deficient Treg cell subset in both Mirn146a//Foxp3KO and
Mirn146a//Ly5.1+B6 mixed chimeras suggested that miR-
146a deficiency increases Treg cell numbers in a cell-autono-
mous manner.
Despite their increased numbers, miR-146a-deficient Treg
cells were unable to restrain activation of miR-146a-sufficient
effector T cells, which was exhibited by high proliferative activity,
an increased CD62Llow cell subset, and high levels of the activa-
tion markers ICOS and CTLA4 (Figure 1H). In agreement with the
histolopathology data and lack of clinical signs of disease, flow
cytometric analysis of control Mirn-146a//Ly5.1+B6 chimeras
showed that both miR-146a-sufficient and -deficient effector
T cells were kept in check by the miR-146a-sufficient Treg cells
present in these mice (Figure 1I). These results suggested an
indispensable role of miR-146a in Treg cell-mediated immuno-
logical tolerance.
miR-146a Deficiency in Treg Cells Resulted
in Dysregulated IFNg Responses
To identify the underlying mechanisms responsible for early fatal
immune-mediated disease observed in Mirn146a//Foxp3KO
chimeras, we first sought to examine whether miR-146a defi-
ciency results in a general impairment of Treg suppression func-Figure 1. miR-146a-Deficient TregCells Failed to Effectively Control Im
(A) Schematic of generation of mixed BM chimeras.
(B) Kaplan-Meyer survival plot of mixed BM chimeras generated upon reconstituti
BM cells. Forty percent of mice inMirn146a//Foxp3KO group died before the d
groups were euthanized and analyzed.
Splenic Treg cell frequencies in Mirn146a//Foxp3KO and Mirn146a//B6 ch
Foxp3KO BM (C) or Ly5.1+ B6 BM (D) 6–7 weeks after BM transfer.
The proportion (E) and absolute numbers (F) of Ly5.1-Foxp3+ Treg cells in indica
(G) The ratios of Ly5.1-Foxp3+ and Ly5.1+Foxp3+ cells in indicated chimeric mic
Expression of activation markers and Ki67 in miR-146a-sufficient Ly5.1+Foxp3
or mirn146a//B6 and mirn146a+/+/B6 BM (I) 6–7 weeks after BM transfer.
Data are representative of three independent experiments (n = 11–13); values rep
Figure S2.tion in inflammatory settings similar to Dicer deficiency in Treg
cells (Liston et al., 2008). To examine this possibility, miR-
146a-deficient Treg cells isolated from healthy Mirn146a//B6
or diseased Mirn146a//Foxp3KO mice were cocultured with
miR-146a-sufficient responder CD4+ T cells. We found that miR-
146a-deficient Treg cells isolated from healthy Mirn146a//B6
chimeras were as suppressive as their miR-146-sufficient
counterparts from control animals, whereas miR-146-deficient
Treg cells from diseased Mirn146a//Foxp3KO mice were
more suppressive in vitro, likely due to their activation in an
inflammatory environment (Figures 2A and 2B). These results
suggested that, unlike Dicer deficiency, lack of miR-146a did
not diminish the overall suppressor capacity of Treg cells
reflected by an in vitro suppression assay. Instead, a particular
aspect of Treg suppressor function was likely impaired in the
absence of miR-146a.
As mentioned earlier, miR-146a functions as a negative regu-
lator of TLR/IL-1 signaling pathway by targeting TRAF6 and
IRAK1/2 (Taganov et al., 2006; Hou et al., 2009). A recent study
demonstrated that IL-1 stimulation results in IL-17 production in
CD4+ T cells including Foxp3+ Treg cells (Chung et al., 2009).
Moreover, a critical role of IRAK1 in promoting Th17 differentia-
tion at the expense of TGFb-dependent generation of peripheral
Foxp3+ Treg cells suggested a possibility that the lack of miR-
146a might lead to heightened Th17 responses, which cause
the fatal autoimmunity in Mirn146a//Foxp3KO chimeras (Mai-
tra et al., 2009). Indeed, in agreement with previous studies we
found increased levels of TRAF6 and IRAK1 in Treg and non-
Treg T cells (Figure S1K). However, we did not observe any
change in either Foxp3 induction or Th17 differentiation in vitro
in the presence or absence of miR-146a (Figure S1L). More
importantly, Th17 cell numbers were similar in Mirn146a//
Foxp3KO and control Mirn146a+/+/Foxp3KO and Mirn146a//
B6 mice (data not shown). Further analysis of cytokine produc-
tion showed that the loss of miR-146a in Treg cells resulted in
increased production of the proinflammatory Th1 cytokine
IFNg by both miR-146a-deficient and -sufficient CD4 and CD8
T cells, whereas production of IL-4, IL-5, and IL-17 was unaf-
fected (Figure 2C; data not shown). This increase was not
observed in the presence of miR-146a-sufficient Treg cells in
Mirn146a//B6 mice (Figure 2F; data not shown). The selective
dysregulation of Th1 responses in the presence of miR-146a-
deficient Treg cells was in contrast to sharply increased produc-
tion of multiple cytokines (IL-2, IL-4, IL-5, IL-17, and IFNg) in the
presence of Dicer-deficient Treg cells (Liston et al., 2008).muneHomeostasis andRestrainmiR-146a-Sufficient Effector TCells
on of irradiated Rag2/ (or TCRbd/) recipients with 1:1 mixtures of indicated
ay of analysis (arrow). The rest of the mice in this group along with other control
imeric mice generated upon transfer of Mirn146a/ BM mixed with Ly5.1+
ted chimeric mice.
e are shown.
Teff cell subsets from mirn146a//Foxp3KO and mirn146a+/ /Foxp3KO (H)
resent the mean ± standard deviation (SD), *p < 0.05. See also Figure S1 and
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Consistent with these findings, purified miR-146a-deficient Treg
cells adoptively transferred together with Foxp3KO CD4+
effector T cells into lymphopenic recipients failed to restrain
Th1 responses (Figure S3).
In addition to a marked increase in IFNg production in miR-
146a-sufficient and -deficient effector T cells, a sizable propor-
tion of miR-146a-deficient Foxp3+ Treg cells produced IFNg in
Mirn146a//Foxp3KO mice (Figures 2C–2E). Production of
IFNg and other effector cytokines by Treg cells is kept in check
by Foxp3 likely as a ‘‘safety’’ feature, since Treg cells express
TCR with an increased reactivity against ‘‘self’’ antigens (Hsieh
et al., 2006). Loss of Foxp3 in Treg cells resulted in the acquisi-
tion of the ability to produce proinflammatory cytokines, and
cause tissue lesions in the absence of functional Treg cells
(Williams and Rudensky, 2007; Zhou et al., 2009). Thus, our
current observations suggested that in addition to Foxp3, miR-
146a prevents acquisition of Th1-like properties by Treg cells,
i.e., restrains production of the proinflammatory cytokine IFNg
by Treg cells.IFNg Blockade Prevents Autoimmune Disease
in Mice Harboring miR-146a-Deficient Treg Cells
Next, we examined whether the augmented IFNg response
was responsible for the autoimmune disease observed in
Mirn146a//Foxp3KO chimeric mice. To address this question,
we neutralized the IFNg activity by treatingmicewith IFNg block-
ing antibody starting 3 weeks after BM transfer (Figure 3A). IFNg
blockade did not affect the increases in miR-146a-deficient Treg
cell numbers (Figure 3B); however, it rescued the disease
observed in their presence. At the time of analysis, treated
Mirn146a//Foxp3KO mice were disease free and phenotypi-
cally indistinguishable from control Mirn146a+/+/Foxp3KO mice
(Figure 3C; data not shown). In contrast, control IgG treated
Mirn146a//Foxp3KO mice developed severe clinical signs of
immune-mediated disease and tissue inflammation (Figure 3C;
data not shown). The effectiveness of IFNg blockade was also
manifested in normalization of the number of T cells expressing
CXCR3, a Th1-specific chemokine receptor (Nakajima et al.,
2002; Barbi et al., 2007), in IFNg antibody-treated mice,
whereas, in IgG-treated animals, CXCR3 expression on effector
and Treg cells remained high (Figure 3C; data not shown). Impor-
tantly, antibody-mediated neutralization of IFNg and rescue
of Th1-mediated disease in Mirn146a//Foxp3KO mice were
not associated with measurable increases in IL-4 or IL-17 (Fig-
ure 3D). These results suggested that miR-146a-deficient Treg
cells were able to restrain Th2 and Th17, but not Th1 responses
and that immune-mediated lesions observed in the presence ofFigure 2. Selective Dysregulation of IFNg Responses in Mice Harborin
miR-146a-deficient or -sufficient Treg cells isolated from (A) healthyMirn146a/
wild-type responder CD4+ T cells at the indicated ratios for 72 hr in the presence
(C) Frequencies of IFNg-secreting cells in Foxp3CD4+ and Foxp3+CD4+ T cells is
effector subset appears tomake somewhat less IFNg as compared with Foxp3ko T
T cells due to the presence of Treg ‘‘wannabe’s’’ (Hsieh et al., 2006).
The proportions (D) and absolute numbers (E) of IFNg-secreting cells in Foxp3+CD
numerated. Data are representative of three independent experiments (n = 11–1
(F) Frequency of IFNgsecreting cells in Foxp3CD4+ and Foxp3+CD4+ T cells i
Data are representative of three independent experiments (n = 11–13). See alsomiR-146a-deficient Treg cells were IFNg dependent. Since an
increase in numbers of miR-146a-deficient Treg cells was unaf-
fected by IFNg neutralization, these experiments also imply that
Treg cell homeostasis and suppressor function are likely
controlled by miR-146a via distinct molecular mechanisms.miR-146a Regulates Stat1 in Treg Cells
Next, we sought to explore molecular mechanisms underlying
miR-146a-dependent Treg cell-mediated Th1 regulation. In
addition to the aforementioned miR-146a targets, TRAF6 and
IRAK1, a recent study has suggested that Stat1 is a miR-146a
target in human PBMCs (Tang et al., 2009). Since Stat1 is
a key transcription factor downstream of IFNg receptor sig-
naling, it was possible that Stat1 expression in miR-146a-
deficient Treg cells was increased and could account for the
IFNg-/Th1-dependent immune-mediated lesions observed in
Mirn146a//Foxp3KO chimeras. However, unlike the 30 UTR
of the human Stat1 gene, which contains a perfect match with
the miR-146a seed sequence, no canonical target sequence
was found in the mouse Stat1 gene. Nevertheless, a highly
conserved sequence with partial complementary to miR-146a
was present in the mouse Stat1 30 UTR (Figure 4A). Although
computational algorithms relying on miRNA seed sequence
analysis failed to identify mouse Stat1 as a miR-146a putative
target, it was recently shown that some microRNAs, like miR-
24, control multiple genes in the absence of canonical target
seed sequences (Lal et al., 2009). Thus, it was possible that
miR-146a might recognize mouse Stat1 through ‘‘seedless’’
yet conserved complementary sequences. Indeed, transfection
of mouse Stat1 30 UTR-containing luciferase reporter into miR-
146a-sufficient, but not miR-146a-deficient T cells showed
repression of reporter activity, which was abolished upon muta-
genesis of the putative miR-146a binding site (Figure 4B). More-
over, miR-146a overexpression in HEK293 cells reduced lucif-
erase reporter activity (data not shown). Finally, we found an
3- to 4-fold increase in total Stat1 protein in both Treg and
non-Treg cells lacking miR-146a. Together, these results sug-
gested mouse Stat1 serves as a target of miR-146a in mouse
T cells (Figure 4C). Levels of phosphorylated Stat1 were also
markedly increased in miR-146a-deficient cells. Consistent
with the rescue from disease, Stat1 phosphorylation returned
to basal level in chimeric mice treated with IFNg antibody,
whereas the total Stat1 amounts were only partially diminished
(Figure 4C). Elevated levels of TRAF6 and IRAK1 in miR-146a-
deficient T cells were largely unaffected by IFNg antibody treat-
ment and, thus, demonstrate the specificity of the observed
effects of IFNg neutralization.g miR-146a-Deficient Treg Cells
/B6 or (B) diseasedMirn146a//Foxp3KO chimeric mice were cocultured with
of CD3 antibody and irradiated T cell-depleted splenocytes.
olated from diseasedMirn146a//Foxp3KO are shown. miR-146a-deficient T
cell subset because the latter contains an increased frequency of self-reactive
4+ Treg cells isolated from diseasedMirn146a//Foxp3KO chimeric mice are
3); values represent the mean ± SD, *p < 0.05.
solated from healthy Mirn146a//B6 mice are shown.
Figure S3.
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Figure 3. IFNg Blockade Rescued Immune-Mediated Pathology in Mice Harboring miR-146a-Deficient Treg Cells
(A) Schematic of IFNg neutralization experiments using BM chimeras.
(B) Splenic Treg cell frequencies in chimeric mice treated with IFNg neutralizing or control antibodies 6 weeks after BM transfer.
(C) Expression of Ki67 and other activation markers in miR-146a-sufficient Ly5.1+Foxp3CD4+ Teff cells isolated from miR-146a-/Foxp3KO mice with IFNg
neutralizing or control antibodies.
(D) Frequency of IFNg-, IL-4-, and IL-17-secreting cells in miR-146a-sufficient Ly5.1+ Foxp3 D4+ Teff cell subsets from indicated chimeric mice with or without
IFNg treatment are shown. Ly5.1+ Foxp3 CD4+ Teff cells isolated from chimeric mice reconstituted with Foxp3KO BM only served as positive control.
Data are representative of two independent experiments (n = 9–12).miR-146a Controls Treg Cell-Mediated Regulation
of IFNg Response through Targeting Stat1
To test the hypothesis that increased Stat1 expression in the
absence of miR-146a is responsible for the observed failure of920 Cell 142, 914–929, September 17, 2010 ª2010 Elsevier Inc.Treg cells to control Th1 response, we conducted a ‘‘loss-of-
function’’ experiment by generating miR-146a-deficient mice
harboring a single functional Stat1 allele (Mirn146a/ Stat1+/).
We cotransferred Mirn146a/ Stat1+/ and Ly5.1+Foxp3KO
bone marrow cells mixed at 1:1 ratio into Rag2- or TCRbd-defi-
cient recipients (Mirn146a/Stat1+//Foxp3KO). As shown in
Figure 4D, both Treg cells and non-Treg T cells isolated from
Mirn146a/Stat1+//Foxp3KO mice exhibited 50% reduction
in total and phosphorylated Stat1 amounts compared to corre-
sponding Mirn146a/Stat1+/+/Foxp3KO controls. As a result,
Mirn146a/Stat1+//Foxp3KO mice developed a much milder
and delayed immune-mediated pathology (Figure 4E; data not
shown). In agreement with a milder disease phenotype, we
observed significantly reduced IFNg secretion by both miR-
146a-sufficient and -deficient effector CD4+ T cells. Further-
more, reduced Stat1 expression markedly diminished IFNg
production by miR-146a-deficient Treg cells (Figure 4F). Inter-
estingly, reduced IFNg production was accompanied by
a substantial increase in IL-4 producing miR-146a-sufficient
and -deficient effector CD4+ T cells in Mirn146a/Stat1+//
Foxp3KO chimeric mice (Figure 4G). Together, these results
provided genetic evidence that miR-146a ensures Treg cell-
mediated control of Th1 responses at least in part through tar-
geting Stat1 and that limiting Stat1 expression in miR-146a-defi-
cient Treg cells moderates these responses.
IFNg Production by miR-146a-Deficient T Cells
Contributes to, but Does Not Fully Account
for, Pathogenic Th1 Responses
inMirn146a//Foxp3KO Mice
The mixed bone marrow transfers using miR-146a-deficient
hematopoietic stem cells revealed an important role for miR-
146a in Treg cells and suggested that miR-146a deficiency in
these cells leads to Th1-mediated disease. However, we cannot
formally exclude potential contribution to the disease by other
miR-146a-deficient cell subsets in addition to Treg cells. In addi-
tion, the generation of miR-146a-deficient ‘‘former’’ Treg cells
due to the loss of Foxp3 by some Treg cells upon adoptive trans-
fer into lymphopenic hosts raises a question as to whether
miR-146a deficiency in Treg cells could solely account for dysre-
gulation of Th1 responses (Figure S3A). Since miR-146a defi-
ciency resulted in a similar level of Stat1 upregulation and activa-
tion in both Treg and effector T cells (Figures 4C and 4D), it is
plausible that IFNg production resulting from unrestrained
Stat1 activation in miR-146a-deficient T effector cells contrib-
uted to the disease in chimeric mice harboring miR-146a-defi-
cient Treg cells. Consistent with this possibility, we found that
miR-146a-deficient T cells exhibited elevated IFNg, but not
IL-4 production upon activation under nonpolarizing Th0 condi-
tion (Figure 5A).
To dissociate a role of miR-146a in Treg cell-mediated
suppression from its role in restraining IFN-g production by T
effector cells, we generated miR-146a-deficient mice lacking
IFNg (Mirn146a/ Ifng/). We transferred Mirn146a/ Ifng/
and Ly5.1+Foxp3KO BM cells mixed at 1:1 ratio into Rag2- or
TCRbd-deficient recipients (Figure 5B). These Mirn146a/
Ifng//Foxp3KO mice allowed us to assess a role of miR-146a
in Treg cell-mediated suppression of pathogenic Th1 responses
without a confounding effect of the IFNg production by miR-
146a-deficient cells. We found that even in the absence of
IFNg supplied by miR-146a-deficient cells, Mirn146a/Ifng//
Foxp3KO developed autoimmune disease accompanied bymarkedly augmented IFNg production by miR-146a-sufficient
CD4+ and CD8+ T cells (Figures 5C and 5D). Consistent with
the increased IFNg production, miR-146a-sufficient effector
CD4+ T cells displayed an activated phenotype along with
elevated CXCR3 expression (Figure 5E). These results provide
further support for the notion that miR-146a plays an indispens-
able role in Treg cell-mediated Th1 regulation. Nevertheless,
it must be noted that miR-146a-sufficient T cells from
Mirn146a/Ifng//Foxp3KO mice produced less IFNg and
were less activated in comparison to those from Mirn146a/
Ifng+/+/Foxp3KO mice. This observation suggested that IFNg
production by miR-146a-deficient cells contributed to, but
did not fully account for the development of severe Th1
pathology in the presence of miR-146a-deficient Treg cells
(Figures 5C and 5D). Thus, miR-146a limits Th1 responses in
two ways: by endowing Treg cells with the ability to suppress
Th1 responses and by negatively regulating T effector cells in
a cell-autonomous manner. Corresponding to this role in the
Th1 response, we found higher levels of miR-146a in both T
effector and Treg cells with Th1-like features (CXCR3+T-bethi)
in comparison to their CXCR3-T-betlow counterparts (Figures
5F–5I).
Unrestrained Stat1 Activation in Treg Cells Results
in IFNg-Mediated Th1 Pathology
Considering that each miRNA regulates multiple targets, it was
important to examine the consequences of altering Stat1 activa-
tion in Treg cells by means other than the manipulation of miR-
146a expression. Therefore, we performed a ‘‘gain-of-function’’
experiment by analyzing mice with a Treg-specific ablation of
SOCS1, a negative regulator of Stat1. Although SOCS1 also
controls other signaling pathways, loss of SOCS1-dependent
negative regulation of Stat1 is the major contributor to the
IFNg-mediated immunopathology in mice with SOCS1 defi-
ciency (Kubo et al., 2003; Alexander et al., 1999; Horino et al.,
2008; Marine et al., 1999). As shown in Figures 6A–6F, increased
Treg cell numbers were observed in Foxp3CreSocs1fl/flmice. This
is likely due to augmented IL-2R/Stat5 signaling (Figure S4;
Lu et al., 2009; Zhan et al., 2009). However, despite this increase
in Treg number, Foxp3CreSocs1fl/fl mice showed clinical signs of
immune-mediated pathology including conjunctivitis, blephari-
tis, and dermatitis by 6 weeks of age (Figure 6G). Furthermore,
both SOCS1-sufficient effector T cells and SOCS1-deficient
Treg cells in Foxp3creSOCS1fl/fl mice exhibited an activated
phenotype (Figures 6H and 6I; data not shown).
Next, we sought to examine effector mechanisms that
account for the disease observed in Foxp3creSOCS1fl/fl mice.
Like miR-146a-deficient Treg cells, SOCS1-deficient Treg cells
had unimpaired in vitro suppression activity (Figure 7A). As
expected SOCS1 deficiency in Treg cells resulted in unre-
strained Stat1 activation in Treg cells (Figure 7B). And similar
to our observations in Mirn146a//FoxP3KO chimeras, these
mice exhibited selectively dysregulated IFNg production by
both Foxp3+ and Foxp3- CD4+ T cell as well as CD8+ T cells. (Fig-
ures 7C and 7D). Although bothMirn146a//Foxp3KO chimeras
and Foxp3creSOCS1fl/fl mice exhibited Th1-related pathology,
clinical disease manifestations were significantly less severe in
the latter mice. A likely explanation for the observed differenceCell 142, 914–929, September 17, 2010 ª2010 Elsevier Inc. 921
Figure 4. Loss of miR-146a-Mediated Stat1 Repression Contributes to the IFNg-Mediated Th1 Pathology in Mice Harboring miR-146a-
Deficient Treg Cells
(A) Multiple species sequence alignment of the Stat1 30 UTR including the putative miR-146a target site sequence (bold).
(B) CD4+ T cells isolated frommiR-146a-deficient or -sufficientmicewere cotransfectedwith a luciferase reporter construct containing wild-type ormutated Stat1
30 UTR and assessed for luciferase activity 24 hr after transfection.
(C) Immunoblot analysis of the Stat1, TRAF6, and IRAK1 protein expression as well as the phosphorylation of Stat1. Densitometric values normalized on the basis
of b-actin expression are indicated below the corresponding lanes; fold increase in normalized target protein expression in the absence of miR-146a with or
without IFNg neutralization in the indicated T cell subsets. Data are representative of two independent experiments.
(D) Immunoblot analysis of total Stat1 as well as the phosphorylated Stat1 protein in mice with Stat1 hemizygosity. Densitometric values normalized on the basis
of b-actin expression as well as fold increase in normalized target protein expression in the indicated T cell subsets are shown below the corresponding lanes.
(E) Kaplan-Meyer survival plot of Rag2/- mice reconstituted with 1:1 mixtures of indicated BM cells. Arrows indicate the time of analysis.
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was that generation of BM chimeras required irradiation and was
accompanied by transient lymphopenia. Indeed, we found that
Foxp3creSOCS1fl/fl /Foxp3KO chimeras generated upon transfer
of Foxp3KO and Foxp3creSOCS1fl/fl BM at 1:1 ratio into Rag2- or
TCRbd-deficient recipients (Figure S5A) exhibited an acceler-
ated kinetics and increased severity of autoimmune disease in
a close resemblance to Mirn146a//Foxp3KO mice (Figures
S5B–S5D).
Together, our studies suggest that elevated miR-146a expres-
sion in Treg cells is required for control of IFNg-mediated Th1
immune responses at least in part through targeting Stat1,
a key molecule in the IFNg signaling pathway. Our results further
imply that excessive effector cytokine signaling in Treg cells may
lead to their failure to suppress the corresponding response and
consequently brings about severe autoimmunity.
DISCUSSION
Diverse molecular mechanisms control the function of Foxp3+
Treg cells, which serve as critical guardians of immune homeo-
stasis. Very recently, miRNA-mediated posttranscriptional regu-
lation of gene expression in Treg cells has attracted considerable
attention because of the devastating failure of immunological
tolerance observed in mice with Treg cell-specific ablation of
Dicer and Drosha-dependent miRNAs (Chong et al., 2008; Liston
et al., 2008; Zhou et al., 2008). These mice, like Foxp3null mice,
which are genetically devoid of Treg cells, develop unprovoked
Th1, Th2, and Th17 responses and die before 4 weeks of age
from severe immune-mediated lesions in a variety of organs
(Chong et al., 2008; Liston et al., 2008; Zhou et al., 2008). In an
effort to identify specific miRNAs contributing to Treg function,
we discovered that miR-155, whose elevated expression in
Treg cells is driven by Foxp3, confers competitive fitness to
Treg cells by increasing sensitivity of IL-2R signaling through
targeting SOCS1. However, miR-155 was dispensable for
suppressor function of Treg cells despite its nonredundant role
in Treg homeostasis (Kohlhaas et al., 2009; Lu et al., 2009).
Another recent study suggested that high level of cAMP expres-
sion in Treg cells is conditional upon low amounts of miR-142-3p
and that forced expression of this miRNA in Treg cells attenuates
their ability to suppress T cell proliferation in vitro (Huang et al.,
2009). However, the striking loss of suppressor function
observed in Dicer-deficient Treg cells is most likely due to loss
of miRNAs that are overrepresented in these cells (Liston et al.,
2008). Here, we demonstrate an essential role for one miRNA,
miR-146a, in Treg cell function in vivo by analyzing chimeric
mice generated upon cotransfer of miR-146a-deficient and
Foxp3-deficient or wild-type B6 bone marrow cells into lympho-
penic recipients. The presence or absence of miR-146a-suffi-
cient Treg cells represented the sole difference between the
resulting Mirn146a//Ly5.1+B6 and Mirn146a//Foxp3KO
mixed chimeras. Chimeric mice harboring only miR-146a-defi-
cient Treg cells, but not mice harboring both miR-146a-deficient
and -sufficient Treg cells, succumbed to severe autoimmune(F and G) Frequency of (F) IFNg- or (G) IL-4-secreting cells in Foxp3CD4+
and mirn146-/-Stat1/+/Foxp3KO chimeric mice.
Data are representative of two independent experiments (n = 13).disease early after bone marrow reconstitution demonstrating
an indispensable role of miR-146a in Treg cell-mediated
suppression.
Foxp3-dependent suppressor program implemented by Treg
cells keeps in check different types of effector immune
responses to ‘‘self’’ antigens and pathogens. Several recent
studies revealed that Treg cells do not seem to execute
a universal hard-wired functional program limiting all kind of
inflammation and immunity but instead these cells exhibit
distinct mechanistic requirements for suppression of particular
classes of the immune response. For example, Irf4, a transcrip-
tion factor required for Th2 differentiation, is expressed in Treg
cells in a Foxp3-dependent manner and endows them with the
ability to suppress Th2 responses (Zheng et al., 2009). Similarly,
the expression of T-bet, another key transcription factor in Th1
effector cell differentiation, is induced in Treg cells in a Stat1-
dependent manner in response to IFNg signaling and enables
them to proliferate, migrate to, and accumulate at the sites of
Th1 responses (Koch et al., 2009). Likewise, we have found
that Treg cell-restricted ablation of Stat3, a transcription
factor required for Th17 induction, leads to uncontrolled
Th17-dependent pathology (Chaudhry et al., 2009). These
studies suggest that in Treg cells distinct suppressor mecha-
nisms are tailored to fit particular tissue and inflammatory
settings by the same transcription factors which guide effector
T cell differentiation in response to similar cues. In this study,
we extended this concept to miRNAs by demonstrating that fatal
immune-mediated lesions observed in the presence of
miR-146a-deficient Treg cells were accompanied by sharply
augmented Th1 responses and were dependent upon increased
amounts of IFNg.
Activation of the transcription factor Stat1 downstream of the
IFNg receptor facilitates differentiation of Th1 cells and forced
expression of a Stat1-encoding transgene in T cells results in
an IFNg-mediated immunopathology (Siebler et al., 2003).
A connection between miR-146a and Stat1, a key transcription
factor in IFNg response, was suggested by two recent studies
implying that Stat1 serves as a miR-146a target in human
lymphocytes and monocytes (Cameron et al., 2008; Tang
et al., 2009). Despite the lack of a canonical miR-146a site in
the 30 UTR of the mouse Stat1 gene, it contains a highly
conserved site with partial complementarity to miR-146a seed
sequence and additional complementarity in the adjacent
sequence. Luciferase reporter assays demonstrated that this
putative miR-146a binding site is crucial for miR-146a-medi-
ated repression of Stat1. In addition, we have currently em-
ployed the HITS-CLIP (high-throughput sequencing of RNA iso-
lated by crosslinking immunoprecipitation) approach to identify
miR targets in T cells. Our preliminary data confirmed the
proposed region for miR-146a binding in the mouse Stat1
gene (data not shown). More importantly, the disease observed
in mice harboring miR-146a-deficient Treg cells was largely
alleviated when miR-146a deficiency was coupled with Stat1
hemizygosity. Finally, important independent confirmation ofand Foxp3+CD4+ T cell subsets in diseased miR-146-/-Stat1+/+/Foxp3KO
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Figure 5. IFNg Production by miR-146a-Deficient T Cells Partially Contributed to but Cannot Account for Th1 Immunopathology
in Mirn146a//Foxp3KO Mice
(A) CD4+CD25CD62Lhi cells isolated fromMirn146a/mice or wild-type littermates were cultured in vitro under Th1/Th2 polarizing conditions. Intracellular IFNg
and IL-4 staining was assessed by FACS analysis. Data are representative of three independent experiments (n = 4–6).
(B) Schematic of generation of mixed BM chimeras.
(C and D) Frequencies of IFNg-secreting cells in (C) CD4+ and (D) CD8+ T cell population isolated from indicated chimeric mice are shown.
(E) Flow cytometric analysis of expression of activation markers and Ki67 in miR-146a-sufficient Ly5.1+Foxp3-CD4+ Teff cells from indicated chimeric mice are
shown. Data are representative of three independent experiments (n = 6–7).
(F–I) Real-time PCR analysis of (F) primary miR-146a, (G) mature miR-146a as well as (H) T-bet and (I) Foxp3 mRNA expression in FACS-purified CXCR3+ and
CXCR3- populations from CD4+CD25+ Treg cells (TR) and CD4
+CD25CD62Lhi-naive T cells (TN).
Data are representative of two independent experiments.
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Figure 6. Phenotypic Analysis of Mice Sub-
jected to Treg Cell-Specific SOCS1 Ablation
Flow-cytometric analysis of (A) thymus and (B)
spleen cells of 6- to 8-week-old Foxp3cre
SOCS1fl/fl mice and wild-type littermates.
Percentages of different thymocyte and spleno-
cyte subsets are shown.
(C–F) Cellularity of the thymus and spleen and the
protportion and absolute numbers of thymus and
splenic Foxp3+CD4+ Treg cells in Foxp3cre
SOCS1fl/fl mice or wild-type littermates are
shown. Data are representative of three indepen-
dent experiments (n = 6–8); values represent the
mean ± SD; *p < 0.05.
(G–I) H&E-stained sections of the skin, liver, and
lung from the indicated chimeric mice. Flow-cyto-
metric analysis of expression of Ki67 and other
activation markers in (H) Foxp3CD4+ Teff cells
and (I) Foxp3+CD4+ Treg cells in 6- to 8-week old
Foxp3creSOCS1fl/fl mice (blue) or wild-type litter-
mates (red). Data are representative of two
independent experiments (n = 6–8).
See also Figure S4.this biological significance of restraining Stat1 activation
in Treg cells for their ability to suppress Th1 responses
was provided by our analysis of Foxp3creSOCS1fl/fl mice and
Foxp3creSOCS1fl/fl/Foxp3KO chimeras. These mice, which
harbor SOCS1-deficient Treg cells, develop IFNg-mediated
Th1 immunopathology similar to that observed in the presence
of miR-146a-deficient Treg cells. Together, these findings offer
genetic support for the notion that miR-146a ensures Treg cell-Cell 142, 914–929, Semediated regulation of Th1 responses,
in a significant part, through targeting
Stat1.
Importantly, analysis of Mirn146a/
Ifng//Foxp3KO and Mirn146a//
Foxp3KO chimeric mice revealed that
miR-146a-deficient Treg cells were
unable to prevent pathogenic Th1
responses and associated disease
regardless in the absence of IFNg sup-
plied by the miR-146a-deficient com-
partment. Nevertheless, these experi-
ments also showed that IFNg
production by miR-146a-deficient T
effector cells contributed to full-scale
Th1 immunopathology in Mirn146a//
Foxp3KO mice. It is noteworthy that
miR-146a was the first identified miRNA
with an increased expression in terminally
differentiated Th1 cells (Monticelli et al.,
2005). Thus, miR-146a-mediated Stat1
repression in activated T effector cells
likely serves as a mechanism of negative
feedback regulation of Th1 responses.
Moreover, our observation of higher
levels of miR-146a in both Treg and
effector T cells with ‘‘Th1-like’’ features(CXCR3+T-bethi) in comparison to their CXCR3-T-betlow counter-
parts suggested that Treg cells further increase miR-146a
expression in Th1 environment to ensure effective suppression
of Th1 responses. Consistent with this model, the presence of
miR-146a-sufficient Treg cells in Mirn146a//Ly5.1+ B6
chimeric mice was able to keep in check Th1-prone effector
T cells derived frommiR-146a-deficient compartment. Together,
our data demonstrated an important role of miR-146a in bothptember 17, 2010 ª2010 Elsevier Inc. 925
Figure 7. Unrestrained Stat1 Activation in SOCS1-Deficient Treg Cells Is Associated with Dysregulated IFNg Responses
(A) SOCS1-deficient or -sufficient Treg cells were cocultured with wild-type responder CD4+ T cells at the indicated ratios for 72 hr in the presence of CD3 anti-
body and irradiated (2000 rads) T cell-depleted splenocytes.
(B) Immunoblot analysis of total and phospho-Stat1. Densitometric values normalized on the basis of b-actin expression and fold increase in normalized target
protein expression in the indicated T cell subsets are indicated below the corresponding lanes.
(C and D) Frequencies of IFNg-secreting cells within Foxp3CD4+ and Foxp3+CD4+ as well as CD8+ subsets in Foxp3creSOCS1fl/flmice or wild-type littermates.
Data are representative of two independent experiments. See also Figure S5.Treg cell-mediated Th1 regulation and in limiting Th1 responses
in a T effector cell-intrinsic manner.
In addition to Stat1, miR-146a was previously shown to nega-
tively regulate TLR/IL-1R signaling pathway in macrophages by
targeting TRAF6 and IRAK1/2 (Hou et al., 2009; Taganov et al.,
2006). Indeed, levels TRAF6 and IRAK1 proteins were increased
in bothmiR-146a-deficient Treg and non-Treg T cells. It has been
shown that IL-1R signaling facilitates Th17 differentiation and
IL-17 production (Chung et al., 2009;Maitra et al., 2009). Further-
more, Th2 responses are also facilitated by signaling through
IL-1R and IL-33R, another TRAF6/IRAK-dependent IL-1R family
member (Ben-Sasson et al., 2009; Schmitz et al., 2005). Thus,
according to the idea of ‘‘symmetry’’ between cues eliciting
effector T cell differentiation and corresponding suppressor
capability in Treg cells, miR-146a deficiency in Treg cells could
also result in augmented Th17 or Th2 responses. However, the
lack of Th2 or Th17 cytokine production in mice harboring
miR-146a-deficient Treg cells and the unimpeded ability of
miR-146a-deficient Treg cells to suppress in vitro proliferative
responses of T cells demonstrated that miR-146a deficiency in
Treg cells results in a selective impairment in their ability to regu-
late Th1 responses. Lack of a detectable increase in Th2 and
Th17 responses in the presence of miR-146a-deficient Treg cells
can be explained by the fact that IFNg/Stat1 signaling, while
promoting Th1 immune response, inhibits the differentiation of
Th2 and Th17 cells (Hu and Ivashkiv, 2009). Thus, it is possible926 Cell 142, 914–929, September 17, 2010 ª2010 Elsevier Inc.that the potential impact of dysregulated TRAF6/IRAK1 signaling
in miR-146a-deficient Treg cells was masked by the dominant
effect of elevated Stat1 expression and activation. In support
of this idea, combined miR-146a deficiency and Stat1 hemi-
zygosity in Treg cells resulted in an increase in IL-4 producing
Th2 cells in addition to the aforementioned decrease in IFNg-
producing Th1 cells.
Although the heightened Stat1 activation associated with
miR-146a and SOCS1 deficiency in Treg cells impaired their
ability to suppress Th1 responses, the numbers of miR-146a-
and SOCS1-deficient Treg cells were markedly increased
compared to their wild-type counterparts. Whereas an increase
in size of SOCS1-deficient Treg subset is most likely a conse-
quence of augmented IL-2R signaling and Stat5 phosphorylation
(Lu et al., 2009), miR-146a deficiency did not alter Stat5 expres-
sion or activation (data not shown). In addition, miR-146a-
deficient Treg cell number was not decreased by the attenuated
Stat1 phosphorylation and inflammation that accompanied
antibody-mediated blockade of IFNg signaling in chimeric
mice, or Stat1 haploinsufficiency. These findings suggested
that de-repression of miR-146a targets other than Stat1 likely
contributed to the increased Treg cell numbers in miR-146a-
deficient mice.
Our findings that miR-146a- or SOCS1-deficient Treg cells fail
to control Th1 responses likely due to unrestrained expression
and activation of Stat1 may appear to fit the aforementioned
concept of ‘‘symmetry’’ in the integration of environmental cues
by Treg and effector T cells. However, whereas in previous
studies it was the lack of Th lineage-specific transcription factors
Stat3, Irf4, and T-bet in Treg cells that resulted in impaired
suppression of Th17, Th2, and Th1 responses, respectively, in
this study unrestrained activation of Stat1 led to immunopa-
thology. Importantly, Stat1 as well as IFNg receptor (IFNgR)
expression in Treg cells are necessary for T-bet induction in
Treg cells, a prerequisite for efficient suppression of Th1
responses (Koch et al., 2009). The observations that both the
lack of Stat1 and unrestrained Stat1 activation resulted in a
breakdown of immunologic tolerance suggested that Treg-
mediated suppression of Th1-mediated immunopathology is
dependent upon a certain optimal range of Stat1 activation by
cytokines. Moreover, by limiting Stat1 amounts in Treg cells,
miR-146a prevents their deviation into IFNg-producing ‘‘Th1-
like’’ cells and thereby, safeguards their function and identity in
inflammatory settings.
Our findings also raise a question as to why miR-146a- or
SOCS1-deficient Treg cells fail to control Th1 responses.
Chemokine receptor CXCR3, a well-characterized target of
T-bet (Beima et al., 2006; Lord et al., 2005), is induced in Treg
cells in a T-bet-dependent manner and endows them with the
ability to migrate to the sites of Th1 responses, a prerequisite
for their efficient regulation (Koch et al., 2009). However,
CXCR3 expression on the surface of Treg cells was elevated in
the absence of miR-146a or SOCS1 consistent with increased
Stat1 activation. This finding leads to the next fundamental ques-
tion as to how do miR-146a- or SOCS1-deficient Treg cells lose
control of Th1 responses. It is possible that IFNg secreted by
Treg cells could facilitate pathogenic Th1 responses since
a sizable fraction of both miR-146a- and SOCS1-deficient Treg
cells produce IFNg. In addition, our previous microarray and
phenotypic analyses have shown that IFNgR is upregulated in
Foxp3+Treg cells versus naive T cells in a Foxp3-dependent
manner. Furthermore, a recent study by the Belkaid group has
demonstrated that during lethal T. gondii infection exposure
of wild-type Treg cells to high amounts of Th1 inflammatory
mediators superimposes Th1 effector program on Treg cells.
Consequently, Treg cells produce IFNg and potentially con-
tribute to the tissue damage leading to death of the infected
host (Oldenhove et al., 2009). Together, these findings raise
a possibility that an autocrine loop amplifies Stat1 activation
and IFNg production in miR-146a- and SOCS1-deficient Treg
cells, and that overt IFNg signaling in miR-146a-deficient and
SOCS1-deficient Treg cells results in the breakdown of a yet
unidentified mechanism of Treg cell-mediated suppression of
Th1 responses. In supporting this notion, reduced pathogenic
Th1 responses were observed in chimeric mice harboring miR-
146a-deficient Treg cells incapable of secreting IFNg. Neverthe-
less, lack of IFNg production by miR-146a-deficient non-Treg
cells precludes clear conclusions drawn from these studies.
Further genetic studies employing Treg cell-specific ablation of
IFNg and IFNgR are required to directly test this idea.
In summary, our studies demonstrated that a single miRNA,
miR-146a, is indispensable for suppression mediated by Treg
cells in vivo. Excessive activation of Stat1 in Treg cells is kept
in check by miR-146a to ensure efficient control of spontaneousIFNg-dependent Th1-mediated immunopathology and prevent
deviation of activated Treg cells into IFNg-producing Th1-like
cells. Similar lesions observed in mice with Treg cell-specific
ablation of SOCS1 lend further support to this notion. Our obser-
vations combined with the previously reported requirement for
Stat1-dependent T-bet induction in Treg cells (Koch et al.,
2009) suggest that a certain optimal range of Stat1 activation
maintained by miR-146a is important for Treg-mediated control
of Th1 responses and that both lack of Stat1 and unrestrained
Stat1 activation in Treg cells lead to a severe failure of immuno-
logic tolerance.EXPERIMENTAL PROCEDURES
Mice
Mirn146a/ (M.P.B., K.D.T., D.S. Rao, L. Yang, M. Kalwani, Y. Garcia-Flores,
M. Luong, A. Devrekanli, J. Xu, G. Sun, J. Tay, P.S. Linsley, and D.B., unpub-
lished data), Foxp3KO (Fontenot et al., 2003), Foxp3YFP-cre (Rubtsov et al.,
2008), SOCS1fl (Tanaka et al., 2008), and Stat1/ (Meraz et al., 1996) mice
were housed under SPF conditions. Disease development was monitored by
frequent visual examination and histopathological analyses. All mice were
used in accordance with guidelines from the Institutional Animal Care
Committee of the Memorial Sloan-Kettering Cancer Center.
Quantitative PCR Analysis
Total RNA (including microRNA) was prepared from FACS purified cells
using miRNeasy kit (QIAGEN). For detecting the miR-146a and miR-146b
expression levels, Taqman ‘‘stem-loop’’ real-time RT-PCR was performed
as demonstrated previously (Jazdzewski et al., 2008). For measuring primary
miR-146a and miR-146b, first strand complementary DNA was synthesized
by using iScript cDNA synthesis kit (Bio-Rad) followed by real-time PCR
analysis (SYBR green; Applied Biosystems).
Generation of Bone Marrow Chimeras Mice and In Vivo
IFNg Neutralization
Mixed bone marrow chimeras were generated as described elsewhere
(Lu et al., 2009). In brief, T cell-depleted bone marrow cells from mice of indi-
cated genotypes were mixed at 1:1 ratio and injected into T cell-deficient
Rag2/ or in some cases Tcrb/Tcrd/ irradiated (950 rads) hosts (3–5 3
106 total cells/recipient). Clinical signs, tissue histology, and the immune cell
subset composition in the thymus and secondary lymphoid tissues were
examined 6 weeks after BM transfer or when mice became moribund. In
some experiments, mixed BM chimeras were administrated i.p. with 0.5 mg
neutralizing IFNg antibody (clone XMG1.2) or isotype-matched control IgG
weekly starting at 3 weeks after BM transfer.
In Vitro Suppression Assay
The ability of miR-146-deficient and -sufficient Treg cells to suppress prolifer-
ative responses of T cells was assessed in a standard in vitro suppression
assay (Liston et al., 2008). In brief, FACS purified 4 3 104 naive Ly5.1
CD4+CD25CD62Lhi T cells andMirn146a+/+orMirn146/Ly5.1CD4+CD25hi
Treg cells isolated from the mixed BM chimeras were mixed at the indicated
ratios and stimulated with CD3 antibody in the presence of irradiated
(2000 rads) splenocytes . T cell proliferation was assessed by with 3H-TdR
incorporation (cpm) in triplicate cultures during the last 8 hr of culture.
Flow Cytometry and Cytokine Secretion Assays
Cell surface staining and flow cytometric analysis of CD4, CD8, CD25, CD62L,
CD103, GITR, ICOS, and CXCR3 (all eBioscience) expression were performed
as described elsewhere (Fontenot et al., 2005). Intracellular staining of Foxp3,
IL-4, IFNg, CTLA-4 (all eBioscience), and Ki67 (BD Bioscience) were per-
formed following fixation and permeabilization according to manufacturer’s
instructions.Cell 142, 914–929, September 17, 2010 ª2010 Elsevier Inc. 927
Tomeasure T cell cytokine production, 23 106 splenocytes were stimulated
in 24-well plates with PMA (50 ng/ml) and ionomycin (250 ng/ml) in the
presence of ‘‘Golgi plug’’ (BD Biosciences) for 5 hr at 37C before staining.
Luciferase Reporter Assay
CD4+ T cells isolated from Mirn146a/ or Mirn146a+/+ mice were cultured in
12-well plates (1 3 106 cells/well) and transfected with psiCheck2 luciferase
reporter plasmids (Promega) containing either wild-type or mutated Stat1 30
UTR using Amaxa mouse T cell nucleofector kit (Lonza, Basel, Switerland).
Cells were harvested 24 hr later and luciferase activity was assessed using
Dual-Luciferase Reporter Assay System (Promega) according to manufac-
turer’s protocol.
Western Blot Analysis
Cell lysates from miR-146a-sufficient or -deficient Ly5.1-CD4+CD25-CD62Lhi
T cells and Ly5.1-CD4+CD25hi Treg cells FACS purified from the mixed BM
chimeras were separated by SDS-PAGE (5 3 105/lane) subjected to western
blot analysis as described previously (Lu et al., 2009). In some experiments,
CD4+Foxp3- T cells or CD4+Foxp3+ T cells isolated from Foxp3creSOCS1fl/fl
mice or control littermates were used. Antibodies against TRAF6 (04-451;
Miliipore), IRAK1 (NBP1-03169; Novus), Stat1 (9172), phospho-Stat1 (9167),
Stat5 (9363), phospho-Stat5 (#9359; all from Cell Signaling Technology), and
b-actin (AC-74, Sigma) were used to visualize the corresponding proteins.
Protein quantitation was performed using NIH Image J software (http://rsb.
info.nih.gov/ij/).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
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